El interés en corto de Connexa Sports Techs da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Connexa Sports Techs. Los datos de interés en corto se actualizan cada dos semanas.

Connexa Sports Techs (NASDAQ:YYAI) Bolsa, Informe de interés en corto

Connexa Sports Technologies Inc. - Common Stock

Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.

Connexa Sports Technologies Inc

Oppenheimer analyst Kristen Owen reiterates Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Outperform and raises the price target from $72 to $75.

News

Price Target

Reiteration

Analyst Ratings

CTVA

Oppenheimer Reiterates Outperform on Corteva, Raises Price Target to $75

HC Wainwright &amp; Co. analyst Andrew Fein maintains Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) with a Buy and raises the price target from $7 to $10.

ALEC

HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $10

WIIM

EMBC

Embecta shares are trading lower. The company reported Q2 financial results.

EVCM

EverCommerce shares are trading higher after the company reported better-than-expected Q1 sales results.

HC Wainwright &amp; Co. analyst Heiko Ihle maintains McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) with a Buy and lowers the price target from $18 to $15.5.

HC Wainwright & Co. Maintains Buy on McEwen Mining, Lowers Price Target to $15.5

Ready Capital shares are trading lower after the company reported worse-than-expected Q1 financial results.

TBPH

Theravance Biopharma shares are trading lower after the company reported worse-than-expected Q1 financial results.

Next Technology Holding Inc. - Ordinary Shares

NXTT

NXXT

CORRECTION: Next Technology Ticker Is "NXTT"

ARKO

ARKO shares are trading higher after the company reported better-than-expected Q1 EPS results.

Trading Ideas

Next Technology Shares Halted On Circuit Breaker To The Upside, Stock Now Up 480.6%

Oppenheimer analyst Jason Helfstein reiterates Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) with a Outperform and lowers the price target from $13 to $12.

COMP

Oppenheimer Reiterates Outperform on Compass, Lowers Price Target to $12

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
&nbsp;
The following table summarizes the Company's digital asset holdings as of:
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">March 31, 2025</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">December&nbsp;31, 2024</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Approximate number of bitcoins held</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>5,833</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>833</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Digital assets carrying value</td>
<td>&nbsp;</td>
<td>$</td>
<td>481,717,253</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>$</td>
<td>78,322,430</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Gain on digital assets during the period/ year</td>
<td>&nbsp;</td>
<td>$</td>
<td>245,311,156</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>$</td>
<td>43,184,854</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
As of March 31, 2025, the Company held approximately 5,833 of bitcoins, which had a carrying value of approximately $481.7 million.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Next Technology Says As Of March 31, 2025, The Company Held ~5,833 Bitcoins, Which Had A Carrying Value Of ~$481.7M, Up From Holdings Of 833 Bitcoin As Of December 31, 2024.

CLFD

Clearfield shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 guidance above estimates.

ASTH

Astrana Health shares are trading lower after the company reported worse-than-expected Q1 financial results.

PACB

Pacific Biosciences shares are trading lower. The company reported Q1 financial results.

Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Peraso to report an earnings per share (EPS) of $-0.16.
Peraso bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 2.75% drop in the share price the following trading session.
Here's a look at Peraso's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.23</td>
<td>-0.36</td>
<td>-1.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.34</td>
<td>-0.88</td>
<td>-0.83</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-20.0%</td>
<td>-11.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746810625_0.png" alt="eps graph" />
<h3>Performance of Peraso Shares</h3>
Shares of Peraso were trading at $0.9257 as of May 08. Over the last 52-week period, shares are down 36.45%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRSO/earnings">To track all earnings releases for Peraso visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

PRSO

Insights into Peraso's Upcoming Earnings

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.
Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $-0.04. 
Harvard Bioscience bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 6.55% drop in the share price the following trading session.
Here's a look at Harvard Bioscience's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>0.03</td>
<td>0.05</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.06</td>
<td>-0.02</td>
<td>0</td>
<td>0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>8.0%</td>
<td>-7.000000000000001%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746810613_0.png" alt="eps graph" />
<h3>Market Performance of Harvard Bioscience's Stock</h3>
Shares of Harvard Bioscience were trading at $0.3046 as of May 08. Over the last 52-week period, shares are down 90.61%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on Harvard Bioscience</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Harvard Bioscience.
Analysts have provided Harvard Bioscience with 1 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $4.5, suggesting a potential 1377.35% upside.
<h3>Comparing Ratings with Competitors</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Bionano Genomics, Akoya Biosciences and Inotiv, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Bionano Genomics, with an average 1-year price target of $7.0, suggesting a potential 2198.1% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Akoya Biosciences, with an average 1-year price target of $2.19, suggesting a potential 618.98% upside.</li>
<li>Analysts currently favor an Buy trajectory for Inotiv, with an average 1-year price target of $5.0, suggesting a potential 1541.5% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Bionano Genomics, Akoya Biosciences and Inotiv are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harvard Bioscience</td>
<td>Outperform</td>
<td>-12.78%</td>
<td>$14.01M</td>
<td>0.03%</td>
</tr>
<tr>
<td>Bionano Genomics</td>
<td>Buy</td>
<td>-23.86%</td>
<td>$3.42M</td>
<td>-47.78%</td>
</tr>
<tr>
<td>Akoya Biosciences</td>
<td>Neutral</td>
<td>-19.42%</td>
<td>$14.39M</td>
<td>-77.25%</td>
</tr>
<tr>
<td>Inotiv</td>
<td>Buy</td>
<td>-11.53%</td>
<td>$25.04M</td>
<td>-16.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Harvard Bioscience ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the top. The consensus rating for Harvard Bioscience is Outperform.
<h3>All You Need to Know About Harvard Bioscience</h3>
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
<h3>Financial Insights: Harvard Bioscience</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Harvard Bioscience's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -12.78%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Harvard Bioscience's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.07%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Harvard Bioscience's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Harvard Bioscience's ROA excels beyond industry benchmarks, reaching 0.01%. This signifies efficient management of assets and strong financial health.
Debt Management: Harvard Bioscience's debt-to-equity ratio is below the industry average. With a ratio of 0.7, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/HBIO/earnings">To track all earnings releases for Harvard Bioscience visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HBIO

Examining the Future: Harvard Bioscience's Earnings Outlook

NextNav shares are trading lower after the company reported worse-than-expected Q1 financial results.

Wedbush analyst Alicia Reese maintains Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) with a Neutral and raises the price target from $9 to $12.

TBCH

Wedbush Maintains Neutral on Turtle Beach, Raises Price Target to $12

Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) reported quarterly earnings of $1.98 per share. This is a 73.42 percent decrease over earnings of $7.45 per share from the same period last year.

Next Technology Holding Q1 EPS $1.98 Down From $7.45 YoY

Press Releases

Connexa Regains Full Nasdaq Compliance

Connexa Reports FY 2024 Audited Financial Results and Provides Review of Operations

Yuanyu Enterprise Management Co., Limited, Reports 1Q2024 Unaudited Financial Results

Yuanyu Enterprise Management announces entry into an exclusive license agreement for its innovative matchmaking technology covering the UK and Europe

Yuanyu Enters $4 Billion Matchmaking Market, Signs $30 Million Licensing Agreement

CONNEXA RECEIVES NASDAQ APPROVAL TO ACQUIRE YUANYU ENTERPRISE MANAGEMENT

CORRECTION NOTICE OF PRESS RELEASE ANNOUNCING RECEIPT OF NASDAQ APPROVAL TO ACQUIRE YUANYU ENTERPRISE MANAGEMENT

CONNEXA HAS CLOSED THE ACQUISITION OF A FURTHER 50% OF YYEM AND CONFIRMS THAT TRADING OF THE POST-ACQUISITION YYAI WILL COMMENCE FRIDAY, NOVEMBER 22, 2024

Connexa Sports Technologies Inc. Expands into Social Networking and Content Creation and Enters Discussions with TikTok in the Middle East and North Africa

Connexa Sports Technologies Inc. Signs Content Creation Agreement with TikTok for the Middle East and North Africa

Comments

Connexa Sports Techs

Interés en corto

Connexa Sports Techs (NASDAQ:YYAI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL